Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.45 |
| ▸ | CDK2 | P24941 | 5/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.42 |
| ▸ | CCR7 | P32248 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817349 | 1.00 | HDAC3 (0.46) | HDAC3HDAC1HDAC2HDAC6CCNE1 | |
| Fumaric Acid SCHEMBL30856933 | 0.92 | HCAR3 (0.42) | HDAC3HDAC1HDAC2HDAC6CCNE1 | |
| SCHEMBL16048397 | 0.90 | HCAR3 (0.49) | HDAC3HDAC1HDAC2HDAC6CCNE1 | |
| SCHEMBL29582918 | 0.90 | HCAR3 (0.49) | HDAC3HDAC1HDAC2HDAC6CCNE1 | |
| SCHEMBL17075516 | 0.88 | HCAR3 (0.48) | HDAC3HDAC1HDAC2HDAC6CCNE1 | |
| Lithium Ion SCHEMBL17075514 | 0.84 | HDAC3 (0.45) | HDAC3HDAC1HDAC2HDAC6CCNE1 | |
| SCHEMBL1936258 | 0.84 | HCAR3 (0.49) | HCAR3CCR7CCR6SIRT6 | |
| SCHEMBL1936260 | 0.84 | HCAR3 (0.49) | HCAR3CCR7CCR6SIRT6 | |
| SCHEMBL2790974 | 0.83 | PCSK9 (0.56) | HDAC3HDAC1HDAC2HDAC6CCNE1 | |
| SCHEMBL3628624 | 0.81 | HCAR3 (0.50) | HCAR3MAPK1CCR7CCR6SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119306708-A | FLT3-HDAC double-target inhibitor and preparation method and application thereof | 山东大学 | 2025-01-14 | — | — | CN | claimed |
| EP-3949952-B1 | PHARMACEUTICAL COMPOSITION | ASTELLAS PHARMA INC (JP) | 2024-07-17 | — | — | EP | claimed |
| US-11938132-B2 | Stable pharmaceutical composition for oral administration | ASTELLAS PHARMA INC. (JP) | 2024-03-26 | — | — | US | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| WO-2025245059-A1 | COMPOSITIONS COMPRISING GSK-3 AND/OR BETA-CATENIN INHIBITORS AND/OR DEGRADERS AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
| CN-119306708-A | FLT3-HDAC double-target inhibitor and preparation method and application thereof | 山东大学 | 2025-01-14 | — | — | CN | disclosed |
| CN-119264119-A | Preparation method and application of FLT3 degradation agent based on pyrazinecarboxamide skeleton | 中国科学院上海有机化学研究所 | 2025-01-07 | — | — | CN | disclosed |
| CN-118984704-A | Pharmaceutical combinations and methods for treating ovarian cancer | 帕特恩电脑公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-115124590-B | PROTAC compounds for targeted degradation of FLT3-ITD mutant proteins, and preparation method and application thereof | 武汉大学中南医院 | 2024-10-22 | — | — | CN | disclosed |
| CN-110536703-B | Combination therapy using anti-AXL antibody-drug conjugates | ADC治疗有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-113677330-B | pharmaceutical composition | 安斯泰来制药株式会社 | 2023-10-31 | — | — | CN | disclosed |
| EP-4230208-A1 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Astellas Pharma Inc. (JP) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022268052-A9 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| CN-116509866-A | Use of diamino heterocyclic carboxamide compounds | 安斯泰来制药株式会社 | 2023-08-01 | — | — | CN | disclosed |
| CN-115772113-A | Preparation method of Gilitinib intermediate, gilitinib intermediate prepared by preparation method and application of Gilitinib intermediate | 上海厚博生物科技有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-115698000-A | Novel pyrazine compounds | 微境生物医药科技(上海)有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-111788197-B | Substituted diamino heterocyclic carboxamide compounds, compositions containing the same and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022268052-A1 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-12-29 | — | — | WO | disclosed |
| CN-115124590-A | PROTAC compound for targeted degradation of FLT3-ITD mutant protein and preparation method and application thereof | 武汉大学中南医院 | 2022-09-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | HDAC3 1207/4885HDAC1 517/4885HDAC2 1853/4885 |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | FLT3, MCL1, JAK2 | HDAC3 198/4885HDAC1 229/4885HDAC2 299/4885 |
| US-11938132-B2 | Stable pharmaceutical composition for oral administration | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 | HDAC3 217/4885HDAC1 156/4885HDAC2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.